Dr. Razis on the Significance of TERT in the Presence of NF1 in GBM
Evangelia Razis, MD, PhD, medical oncologist, Hygeia Hospital, Athens, Greece, discusses the significance of TERT mutations in the presence of NF1 mutations in patients with glioblastoma (GBM).
Dr. Razis on Molecular Targeting of Glioblastoma
Evangelia Razis, MD, PhD, medical oncologist, Hygeia Hospital, Athens, Greece, discusses the importance of molecular targeting for patients with glioblastoma.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512